<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bone marrow transplantation with a small to medium-sized single hospital team is feasible </plain></SENT>
<SENT sid="1" pm="."><plain>It leads to results similar to those observed at large centers and with the same major risk factors: age, stage of the disease at the time of transplant, degree of histocompatibility, <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> prevention method, and selection </plain></SENT>
<SENT sid="2" pm="."><plain>A single small to medium-sized center cannot conduct prospective randomized studies but it can pioneer new concepts </plain></SENT>
<SENT sid="3" pm="."><plain>Bone marrow transplantation today offers a good choice for patients suffering from otherwise lethal <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">bone marrow diseases</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>These include severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, <z:hpo ids='HP_0002488'>acute leukemias</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005526'>lymphoid leukemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and <z:e sem="disease" ids="C0242354" disease_type="Disease or Syndrome" abbrv="">congenital disorders</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Changes in outcome are due to innovative steps, such as the introduction of CsA for GvHD prevention </plain></SENT>
<SENT sid="6" pm="."><plain>In addition they are certainly influenced by unrecognized changes in the patient selection process </plain></SENT>
</text></document>